Escaping the catch 22 of lupus anticoagulant testing.

RMD Open
Pernille Just Vinholt, Søren Andreas Just

Abstract

High-risk patients with antiphospholipid syndrome (APS) experience increased risk of thrombosis when treated with direct oral anticoagulant (DOAC) therapy compared with warfarin. It is essential to establish the APS diagnosis to choose therapy and determine treatment duration. It requires testing for antiphospholipid antibodies, including lupus anticoagulant (LAC). In this viewpoint, we discuss the options for timing of LAC testing, which includes testing before starting anticoagulant treatment (DOAC or warfarin), after switching to heparin or after withdrawal of anticoagulant treatment. DOACs interfere with LAC testing and recommendations emerge stating not to conduct on-therapy LAC testing. All approaches are to some extent currently practised, but have limitations and the area is therefore seemingly a catch 22. We put forward that the anticoagulant effect of DOAC can be eliminated in the laboratory and therefore patients can be tested on-therapy. While it may not eliminate all cases of interference, it could aid the interpretation in these situations and this approach is attractive from the patient and clinician's perspective. Nevertheless, to prevent misdiagnosis the diagnostic workup for APS requires collaboration between ...Continue Reading

References

Sep 9, 2005·American Journal of Clinical Pathology·Jonathan R Genzen, Jonathan L Miller
Jul 25, 2009·Journal of Thrombosis and Haemostasis : JTH·V PengoUNKNOWN Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the Interna
Apr 15, 2016·Thrombosis and Haemostasis·Franz RatzingerPeter Quehenberger
Jun 24, 2017·Thrombosis and Haemostasis·Aleksandra AntovicJovan Antovic
Feb 7, 2018·Thrombosis Research·T ExnerM Ahuja
Jul 14, 2018·Blood·Vittorio PengoAlessandra Banzato
Nov 24, 2018·International Journal of Laboratory Hematology·Sean Platton, Christina Hunt
Dec 19, 2018·The Lancet. Haematology·Corinne Frere, Dominique Farge
Jun 30, 2019·TH Open : Companion Journal to Thrombosis and Haemostasis·Julien FavresseFrançois Mullier
Jul 5, 2019·Journal of Thrombosis and Haemostasis : JTH·Hannah CohenUNKNOWN International Society for Thrombosis and Haemostasis Scientific and Standardization Committee for Lupus Anticoagulant/Antiph
Sep 17, 2019·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·L SlavikM Palova
Oct 28, 2019·Autoimmunity Reviews·Hagit PelegGentian Denas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Related Papers

Journal of Cataract and Refractive Surgery
Robert A Blum, Dan Lindfield
Nature Clinical Practice. Rheumatology
Maria Laura BertolacciniGraham R V Hughes
Journal of Thrombosis and Haemostasis : JTH
Hannah CohenDavid Isenberg
© 2021 Meta ULC. All rights reserved